• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半合成卡那霉素B衍生物阿贝卡星对耐甲氧西林金黄色葡萄球菌的活性。

Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.

作者信息

Hamilton-Miller J M, Shah S

机构信息

Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK.

出版信息

J Antimicrob Chemother. 1995 Jun;35(6):865-8. doi: 10.1093/jac/35.6.865.

DOI:10.1093/jac/35.6.865
PMID:7559197
Abstract

Arbekacin (1-N-((S)-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B) was active against 54 strains of methicillin-resistant Staphylococcus aureus from 16 different countries, all of which were resistant to > or = 32 mg/L amikacin. MICs of arbekacin ranged from 1 to 16 mg/L, the MIC50 was 3.2 mg/L and the mode geometric mean MICs were 4 and 4.5 mg/L respectively.

摘要

阿贝卡星(1-N-((S)-4-氨基-2-羟基丁酰基)-3',4'-二脱氧卡那霉素B)对来自16个不同国家的54株耐甲氧西林金黄色葡萄球菌有活性,所有这些菌株对阿米卡星的耐药浓度均≥32mg/L。阿贝卡星的最低抑菌浓度(MIC)范围为1至16mg/L,MIC50为3.2mg/L,几何平均MIC的众数分别为4mg/L和4.5mg/L。

相似文献

1
Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.半合成卡那霉素B衍生物阿贝卡星对耐甲氧西林金黄色葡萄球菌的活性。
J Antimicrob Chemother. 1995 Jun;35(6):865-8. doi: 10.1093/jac/35.6.865.
2
A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 1998 Apr;41(4):495-7. doi: 10.1093/jac/41.4.495.
3
New 2''-amino derivatives of arbekacin, potent aminoglycoside antibiotics against methicillin-resistant Staphylococcus aureus.阿贝卡星的新型2''-氨基衍生物,对耐甲氧西林金黄色葡萄球菌有效的氨基糖苷类抗生素。
J Antibiot (Tokyo). 1993 Mar;46(3):531-4. doi: 10.7164/antibiotics.46.531.
4
In vitro activity of arbekacin against clinical isolates of methicillin-resistant Staphylococcus aureus in a hospital.阿贝卡星对某医院耐甲氧西林金黄色葡萄球菌临床分离株的体外活性
J Antibiot (Tokyo). 1994 Apr;47(4):507-9. doi: 10.7164/antibiotics.47.507.
5
[Arbekacin resistant gene, aacA/aphD, in Staphylococcus aureus is lost during in vitro passage].
Rinsho Byori. 2002 Jan;50(1):79-84.
6
Susceptibility of methicillin-resistant Staphylococcus aureus clinical isolates to various antimicrobial agents. II. Isolation of arbekacin-resistant strain.
Hiroshima J Med Sci. 1992 Dec;41(4):79-85.
7
Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus.新型氨基糖苷类抗生素阿贝卡星对耐甲氧西林金黄色葡萄球菌的抗菌活性
Drugs Exp Clin Res. 1994;20(6):233-9.
8
In vitro activities of arbekacin, alone and in combination, against methicillin-resistant Staphylococcus aureus.
Jpn J Antibiot. 1994 Jun;47(6):710-9.
9
Specificity of 4'''-acetylation by an aminoglycoside-modifying enzyme in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.
Tohoku J Exp Med. 1998 Sep;186(1):67-70. doi: 10.1620/tjem.186.67.
10
[Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group].[用阿贝卡星治疗耐甲氧西林金黄色葡萄球菌引起的外科感染。阿贝卡星研究组]
Jpn J Antibiot. 1994 Jun;47(6):826-36.

引用本文的文献

1
Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus.阿贝卡星与万古霉素治疗耐甲氧西林金黄色葡萄球菌所致慢性化脓性中耳炎的比较
J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13.
2
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.阿贝卡星与万古霉素治疗皮肤及软组织耐甲氧西林金黄色葡萄球菌感染的疗效及安全性:初步研究
Infect Chemother. 2013 Mar;45(1):62-8. doi: 10.3947/ic.2013.45.1.62. Epub 2013 Mar 29.
3
The usefulness of arbekacin compared to vancomycin.
阿贝卡星相对于万古霉素的有用性。
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29.
4
Population pharmacokinetics of arbekacin in burn patients.阿贝卡星在烧伤患者中的群体药代动力学。
Eur J Clin Pharmacol. 2008 Jun;64(6):599-603. doi: 10.1007/s00228-008-0470-1.
5
Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌感染患者中阿贝卡星的群体药代动力学。
Antimicrob Agents Chemother. 2006 Nov;50(11):3754-62. doi: 10.1128/AAC.00420-05.
6
Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.基于阿贝卡星的联合用药对万古霉素异质性中介金黄色葡萄球菌的协同作用。
J Korean Med Sci. 2006 Apr;21(2):188-92. doi: 10.3346/jkms.2006.21.2.188.
7
Versatility of aminoglycosides and prospects for their future.氨基糖苷类药物的多功能性及其未来前景。
Clin Microbiol Rev. 2003 Jul;16(3):430-50. doi: 10.1128/CMR.16.3.430-450.2003.
8
Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan.通过药敏试验鉴定氨基糖苷类修饰酶:日本耐甲氧西林金黄色葡萄球菌的流行病学
J Clin Microbiol. 2001 Sep;39(9):3115-21. doi: 10.1128/JCM.39.9.3115-3121.2001.
9
Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.氨苄西林联合阿贝卡星治疗由耐高水平庆大霉素的粪肠球菌菌株引起的实验性兔心内膜炎的疗效。
Antimicrob Agents Chemother. 2000 Sep;44(9):2545-6. doi: 10.1128/AAC.44.9.2545-2546.2000.
10
Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality.在血液透析患者透析前即刻给予氨基糖苷类药物:一种新的给药方式。
Antimicrob Agents Chemother. 1997 Dec;41(12):2597-601. doi: 10.1128/AAC.41.12.2597.